Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Tirzepatide

SURMOUNT-1

Eli Lilly · Phase 3 · Recruiting · Enrollment 2539

NCT07481747

ArmPopulationDoseWeeksEstimandWeight change
Arm 1: Tirzepatide 5 mg once weekly + lifestyle interventionObesity, no T2D5 mg72n/rn/r
Arm 2: Tirzepatide 10 mg once weekly + lifestyle interventionObesity, no T2D10 mg72n/rn/r
Arm 3: Tirzepatide 15 mg once weekly + lifestyle interventionObesity, no T2D15 mg72n/rn/r
Arm 4: Placebo once weekly + lifestyle interventionObesity, no T2Dn/r72n/rn/r